Sakura S. Schweizer
YOU?
Author Swipe
View article: Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase
Auranofin Resistance in Toxoplasma gondii Decreases the Accumulation of Reactive Oxygen Species but Does Not Target Parasite Thioredoxin Reductase Open
Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including Toxoplasma go…
View article: Auranofin resistance in<i>Toxoplasma gondii</i>decreases the accumulation of reactive oxygen species but does not target parasite thioredoxin reductase
Auranofin resistance in<i>Toxoplasma gondii</i>decreases the accumulation of reactive oxygen species but does not target parasite thioredoxin reductase Open
Auranofin, a reprofiled FDA-approved drug originally designed to treat rheumatoid arthritis, has emerged as a promising anti-parasitic drug. It induces the accumulation of reactive oxygen species (ROS) in parasites, including Toxoplasma go…